NYSE:ENZ) reported today that new data on the first individual treated in the Phase 1 clinical trial of HGTV-43, the Company's
HIV-1 gene medicine product, show that after nine-and-one-half-months Enzo engineered cells have successfully engrafted in the patient's bone marrow and were spawning new differentiated CD4+ cells designed to fight the virus.